Considerations in Demonstrating Value in the Oncology Clinical Setting

Thought Leaders:

Kathleen McConnell, RPh, MBA, Managing Director, Scifluent, Cello Health Communications
Jason McDonough, PhD, SVP Medical Strategy, Cello Health Communications

January 26, 2016

Incorporating HEOR evidence into oncology drug development pathways is no longer optional, but essential. In this session we identify the reasons for increased importance of demonstrating value in an oncology clinical setting, discuss the ways in which HEOR evidence is the best mechanism to address this challenge, and challenge those involved in oncology drug development to reconsider allocation of resources to HEOR studies over exploratory clinical studies.

Length: 23:29       Size: 10.7MB

Post a Comment

You must be logged in to post a Comment.

FEEDBACK